Search Within

Matthew J Matasar

  1. "Steven Horwitz"
  2. "Heiko Schoder"
  3. "Craig Moskowitz"
Formats
  1. Meeting Abstract (9)
  2. Journal Article (8)
Groups
  1. Center for Hematologic Malignancies (17)
  2. Department of Medicine (17)
  3. Hematologic Malignancies, Division of (17)
  4. Lymphoma (17)
  5. Molecular Imaging and Therapy Service (17)
  6. Population Sciences Research Program (17)

More Groups

People
  1. Andrew Zelenetz (17)
  2. Craig Moskowitz (17)
  3. David Straus (17)
  4. Heiko Schoder (17)
  5. Paul Hamlin (17)
  6. Steven Horwitz (17)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2020 (1)
  5. 2017 (5)
  6. 2016 (3)

More Years

Publications
  1. Blood (6)
  2. Journal of Clinical Oncology (3)
  3. Hematological Oncology (2)
  4. Annals of Oncology (1)
  5. Cancers (1)
  6. Clinical Cancer Research (1)

More Publications

Publishers
  1. American Society of Hematology (6)
  2. American Society of Clinical Oncology (3)
  3. Wiley Blackwell (2)
  4. American Association for Cancer Research (1)
  5. Elsevier Science, Inc. (1)
  6. Ferrata Storti Foundation (1)

More Publishers

Results (17)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Prospective study of 3′-deoxy-3′-(18)F-fluorothymidine PET for early interim response assessment in advanced-stage B-cell lymphoma
    Journal Article

    Schoder, H.; Zelenetz, A. D.; Hamlin, P.; Gavane, S.; Horwitz, S.; Matasar, M.; Moskowitz, A.; Noy, A.; Palomba, L.; Portlock, C.; more...
    Journal of Nuclear Medicine (2016)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Journal Article

    Moskowitz, C. H.; Matasar, M. J.; Zelenetz, A. D.; Nimer, S. D.; Gerecitano, J.; Hamlin, P.; Horwitz, S.; Moskowitz, A. J.; Noy, A.; Palomba, L.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • Risk-adapted therapy using biopsy confirmation of abnormal interim FDG-PET for patients with advanced stage diffuse large B cell lymphoma (DLBCL), and exploratory evaluation of FLT-PET
    Meeting Abstract

    Moskowitz, C. H.; Schoder, H.; Hamlin, P. A.; Gerecitano, J. F.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M.; Portlock, C. S.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save